Clinical perspectives of PSMA PET/MRI for prostate cancer

Detalhes bibliográficos
Autor(a) principal: Barbosa, Felipe de Galiza
Data de Publicação: 2019
Outros Autores: Queiroz, Marcelo Araújo, Nunes, Rafael Fernandes, Marin, José Flávio Gomes, Buchpiguel, Carlos Alberto, Cerri, Giovanni Guido
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Clinics
Texto Completo: https://www.revistas.usp.br/clinics/article/view/154809
Resumo: Prostate cancer imaging has become an important diagnostic modality for tumor evaluation. Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) has been extensively studied, and the results are robust and promising. The advent of the PET/magnetic resonance imaging (MRI) has added morphofunctional information from the standard of reference MRI to highly accurate molecular information from PET. Different PSMA ligands have been used for this purpose including 68gallium and 18fluorine-labeled PET probes, which have particular features including spatial resolution, imaging quality and tracer biodistribution. The use of PSMA PET imaging is well established for evaluating biochemical recurrence, even at low prostate-specific antigen (PSA) levels, but has also shown interesting applications for tumor detection, primary staging, assessment of therapeutic responses and treatment planning. This review will outline the potential role of PSMA PET/MRI for the clinical assessment of PCa.
id USP-19_b7584077c5bc25cd07a97517bc16f830
oai_identifier_str oai:revistas.usp.br:article/154809
network_acronym_str USP-19
network_name_str Clinics
repository_id_str
spelling Clinical perspectives of PSMA PET/MRI for prostate cancerProstate CancerPositron Emission Tomography/Magnetic Resonance ImagingDiagnostic ImagingTumor StagingLocal Neoplasm RecurrenceProstate cancer imaging has become an important diagnostic modality for tumor evaluation. Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) has been extensively studied, and the results are robust and promising. The advent of the PET/magnetic resonance imaging (MRI) has added morphofunctional information from the standard of reference MRI to highly accurate molecular information from PET. Different PSMA ligands have been used for this purpose including 68gallium and 18fluorine-labeled PET probes, which have particular features including spatial resolution, imaging quality and tracer biodistribution. The use of PSMA PET imaging is well established for evaluating biochemical recurrence, even at low prostate-specific antigen (PSA) levels, but has also shown interesting applications for tumor detection, primary staging, assessment of therapeutic responses and treatment planning. This review will outline the potential role of PSMA PET/MRI for the clinical assessment of PCa.Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo2019-02-15info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/clinics/article/view/15480910.6061/clinics/2018/e586sClinics; Vol. 73 No. Suppl. 1 (2018); e586sClinics; v. 73 n. Suppl. 1 (2018); e586sClinics; Vol. 73 Núm. Suppl. 1 (2018); e586s1980-53221807-5932reponame:Clinicsinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/clinics/article/view/154809/150796Copyright (c) 2019 Clinicsinfo:eu-repo/semantics/openAccessBarbosa, Felipe de GalizaQueiroz, Marcelo AraújoNunes, Rafael FernandesMarin, José Flávio GomesBuchpiguel, Carlos AlbertoCerri, Giovanni Guido2019-05-14T11:48:25Zoai:revistas.usp.br:article/154809Revistahttps://www.revistas.usp.br/clinicsPUBhttps://www.revistas.usp.br/clinics/oai||clinics@hc.fm.usp.br1980-53221807-5932opendoar:2019-05-14T11:48:25Clinics - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv Clinical perspectives of PSMA PET/MRI for prostate cancer
title Clinical perspectives of PSMA PET/MRI for prostate cancer
spellingShingle Clinical perspectives of PSMA PET/MRI for prostate cancer
Barbosa, Felipe de Galiza
Prostate Cancer
Positron Emission Tomography/Magnetic Resonance Imaging
Diagnostic Imaging
Tumor Staging
Local Neoplasm Recurrence
title_short Clinical perspectives of PSMA PET/MRI for prostate cancer
title_full Clinical perspectives of PSMA PET/MRI for prostate cancer
title_fullStr Clinical perspectives of PSMA PET/MRI for prostate cancer
title_full_unstemmed Clinical perspectives of PSMA PET/MRI for prostate cancer
title_sort Clinical perspectives of PSMA PET/MRI for prostate cancer
author Barbosa, Felipe de Galiza
author_facet Barbosa, Felipe de Galiza
Queiroz, Marcelo Araújo
Nunes, Rafael Fernandes
Marin, José Flávio Gomes
Buchpiguel, Carlos Alberto
Cerri, Giovanni Guido
author_role author
author2 Queiroz, Marcelo Araújo
Nunes, Rafael Fernandes
Marin, José Flávio Gomes
Buchpiguel, Carlos Alberto
Cerri, Giovanni Guido
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Barbosa, Felipe de Galiza
Queiroz, Marcelo Araújo
Nunes, Rafael Fernandes
Marin, José Flávio Gomes
Buchpiguel, Carlos Alberto
Cerri, Giovanni Guido
dc.subject.por.fl_str_mv Prostate Cancer
Positron Emission Tomography/Magnetic Resonance Imaging
Diagnostic Imaging
Tumor Staging
Local Neoplasm Recurrence
topic Prostate Cancer
Positron Emission Tomography/Magnetic Resonance Imaging
Diagnostic Imaging
Tumor Staging
Local Neoplasm Recurrence
description Prostate cancer imaging has become an important diagnostic modality for tumor evaluation. Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) has been extensively studied, and the results are robust and promising. The advent of the PET/magnetic resonance imaging (MRI) has added morphofunctional information from the standard of reference MRI to highly accurate molecular information from PET. Different PSMA ligands have been used for this purpose including 68gallium and 18fluorine-labeled PET probes, which have particular features including spatial resolution, imaging quality and tracer biodistribution. The use of PSMA PET imaging is well established for evaluating biochemical recurrence, even at low prostate-specific antigen (PSA) levels, but has also shown interesting applications for tumor detection, primary staging, assessment of therapeutic responses and treatment planning. This review will outline the potential role of PSMA PET/MRI for the clinical assessment of PCa.
publishDate 2019
dc.date.none.fl_str_mv 2019-02-15
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/clinics/article/view/154809
10.6061/clinics/2018/e586s
url https://www.revistas.usp.br/clinics/article/view/154809
identifier_str_mv 10.6061/clinics/2018/e586s
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/clinics/article/view/154809/150796
dc.rights.driver.fl_str_mv Copyright (c) 2019 Clinics
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2019 Clinics
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
publisher.none.fl_str_mv Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
dc.source.none.fl_str_mv Clinics; Vol. 73 No. Suppl. 1 (2018); e586s
Clinics; v. 73 n. Suppl. 1 (2018); e586s
Clinics; Vol. 73 Núm. Suppl. 1 (2018); e586s
1980-5322
1807-5932
reponame:Clinics
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Clinics
collection Clinics
repository.name.fl_str_mv Clinics - Universidade de São Paulo (USP)
repository.mail.fl_str_mv ||clinics@hc.fm.usp.br
_version_ 1800222764064309248

Registros relacionados